Metagenomi Therapeutics (MGX) Accounts Payables (2023 - 2026)

Metagenomi Therapeutics (MGX) has 4 years of Accounts Payables data on file, last reported at $2.4 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $2.4 million, down 10.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.4 million (down 10.19% YoY), and the FY2025 annual result was $1.5 million, up 179.36% from the prior year.
• Accounts Payables grew to $2.4 million in Q1 2026 per MGX's latest filing, from $1.5 million in the prior quarter.
• Over five years, Accounts Payables peaked at $6.8 million in Q1 2024 and troughed at $533000.0 in Q4 2024.
• A 4-year average of $2.6 million and a median of $2.5 million in 2025 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2024 and 2025: Accounts Payables plunged 70.24% in 2024, then jumped 179.36% in 2025.
• A 4-year view of Accounts Payables shows it stood at $1.8 million in 2023, then sank by 70.24% to $533000.0 in 2024, then jumped by 179.36% to $1.5 million in 2025, then jumped by 61.05% to $2.4 million in 2026.
• Business Quant data shows MGX's Accounts Payables at $2.4 million in Q1 2026, $1.5 million in Q4 2025, and $1.2 million in Q3 2025.